Arcutis Biotherapeutics, Inc. reported $464M of revenue over the trailing twelve months, +76% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $464M (to Q2 2026). Net income: $29M, trailing twelve months to Q2 2026. Free cash flow: $39M, trailing twelve months to Q2 2026. Operating margin: 6.7%, trailing twelve months to Q2 2026.

ARQTArcutis Biotherapeutics, Inc.

Healthcare

$26.56+53% 1Y

$26.56

$16.7352 weeks$31.20

Latest close: back above its 200-day averageOct 9, 2026what changed →

ARQT as reported

Arcutis Biotherapeutics, Inc. reported $464M of revenue over the trailing twelve months, +76% on the year before. 10 reported series are charted on this page, each one as filed.

$464M

Revenue, trailing twelve months · to Q2 2026 · +76% against the twelve months before

Net income: $29M
Net income · −131% year on year · trailing twelve months to Q2 2026
Free cash flow: $39M
Free cash flow · −159% year on year · trailing twelve months to Q2 2026
Operating margin: 6.7%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for ARQT, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$464M	+76%	Q2 2026
Net income	$29M	−131%	Q2 2026
EPS	$0.21	−128%	Q2 2026
Gross margin	91%	n/a	Q2 2026
Operating margin	6.7%	n/a	Q2 2026
Net margin	5.4%	n/a	Q2 2026
ROE	−6.2%	n/a	Q2 2026
ROA	−2.6%	n/a	Q2 2026
ROIC	−4.8%	n/a	Q2 2026
Free cash flow	$39M	−159%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.